Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 50Terminated 12Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1

Interventions

pembrolizumab 87Cyclophosphamide 75Nivolumab 56Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 42Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 27Paclitaxel 27Ipilimumab 26Cisplatin 24Radiation 23Dexamethasone 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 18Bevacizumab 17Pemetrexed 16130-nm albumin-bound paclitaxel 16palbociclib 15Decitabine 15Cytarabine 15ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Lapatinib × Clear all
NCT01947023 2026-05-14

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
23 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡